Biomedical engineering professor and BIO5 Institute Director Jennifer Barton has spent nearly a decade developing a falloposcope to detect ovarian cancer in its early stages. Banner – University Medical Center surgeon Dr. John Heusinkveld has now used the device to capture images of study participants’ fallopian tubes for the first time.
Jennifer Barton, director of the University of Arizona BIO5 Institute and Thomas R. Brown Distinguished Chair in Biomedical Engineering, has spent years developing a device small enough to image the fallopian tubes. (Chris Richards/University of Arizona)
Due to a lack of effective screening and diagnostic tools, more than three-fourths of ovarian cancer cases are not found until the cancer is in an advanced stage. As a result, fewer than half of all women with ovarian cancer survive more than five years after diagnosis.
Jennifer Barton, director of the University of Arizona BIO5 Institute and Thomas R. Brown Distinguished Chair in Biomedical Engineering, has spent years developing a device small enough to image the fallopian tubes – narrow ducts connecting the uterus to the ovaries – and search for signs of early-stage cancer. Dr. John Heusinkveld has now used the new imaging device in study participants for the first time, as part of a pilot human trial.
For the pilot human trial, Heusinkveld is using the falloposcope device to image the fallopian tubes of volunteers who are already having their tubes removed for reasons other than cancer. This will allow researchers not only to test the effectiveness of the device, but also to start establishing a baseline range of what “normal” fallopian tubes should look like. Since September, Heusinkveld has successfully used the falloposcope in four volunteers.
The FDA has labeled the study as having “nonsignificant risk,” but testing the device on an organ that’s about to be removed reduces the risk even more.
“This is the first endoscope that can fit inside a fallopian tube and actually see anything below the surface with high resolution,” said Heusinkveld, an assistant professor of obstetrics and gynecology at the College of Medicine – Tucson and a board-certified specialist in female pelvic medicine and reconstructive surgery in Banner – University Medical Center Tucson’s Department of Obstetrics and Gynecology. “We were very pleased with the images the device was able to capture in its first inpatient uses, and we look forward to gathering more data.”
At 0.8 millimeters in diameter, the falloposcope’s small size and high resolution are unprecedented.
“It’s itty bitty,” said Barton, who also holds appointments in optical sciences and medical imaging, and is a member of the UArizona Cancer Center. “You just couldn’t have fabricated something like this, even six, seven years ago.”
Saving many lives, improving others
The American Cancer Society estimates that, in 2022, about 19,880 women in the United States will receive a diagnosis of ovarian cancer, and about 12,810 will die from the disease. Barton hopes her falloposcope will help save the lives of some women and vastly improve quality of life for others.
With early-stage detection, doctors could perform prophylactic salpingo-oophorectomies – removal of the ovaries and fallopian tubes – before ovarian cancer spreads. Because researchers believe ovarian cancer usually starts in the fallopian tubes, many physicians recommend that women at risk for ovarian cancer have their ovaries and fallopian tubes removed. Many women opt for the surgery because of its potentially lifesaving benefits, but it isn’t without drawbacks. The procedure thrusts women into surgically induced menopause, with side effects including hot flashes, mood swings, and higher risk of heart and bone disease.
Barton cited one example of a study in which 122 patients who were known carriers of genes that increased their risk for cancer had their fallopian tubes removed as a precaution. Analysis of the tubes after removal showed that only seven of the women were in the process of developing cancer.
“This device could allow us to tell those other 115 women, ‘Hey, you are perfectly normal, and we’ll come back and check on you every couple of years to make sure everything is OK,” Barton explained.
Regular falloposcope screenings could mean that even patients who do ultimately opt for the removal procedure could do it later in life – for example, after childbearing years.
“Anecdotally, I can tell you that when a patient has her ovaries removed at a young age – almost always for cancer risk reduction – she is placed on supplemental hormones, and a significant percentage of them come back and say, ‘You know, I just don’t feel as good as I did,'” Heusinkveld said. “And there’s nothing you can do about that, aside from fiddling around with dosage. So, if we can delay removing ovaries until an age where they’re truly inactive, that’s going to be a pretty big health benefit.”
Years in the making
The falloposcope’s effectiveness stems from a combination of multiple imaging techniques. Through a method called fluorescence imaging, which measures the way different molecules absorb and emit light, the device examines metabolic and functional changes in tissue. With optical coherence tomography, the device observes structural changes at high resolution. A third technique – white light reflectance imaging – gathers information about tissue based on the way it reflects light.
In the initial study, the research team hopes to image 20 sets of fallopian tubes before removal. As the surgeon, Heusinkveld will provide feedback to the engineering team about how to make the device easier to use and more effective.
“The goal here is to show that we can get into the fallopian tubes – which is nontrivial itself – take images, assess the quality of the images and get physician feedback,” Barton said. “This study will help establish a baseline of the range of what ‘normal’ looks like.”
In the future, with FDA approval, the team’s goal is to use the device to image fallopian tubes in patients with a high cancer risk. While it will likely be several years before the device is FDA approved, manufactured and available on the market, this milestone represents a critical step forward in a process that has been over a decade in the making – and could ultimately change ovarian cancer screening protocols forever.
The work to develop a clinical translation of the device has been funded by the U.S. Army since 2018. Barton also is working with Tech Launch Arizona, the UArizona office that commercializes inventions stemming from university research, on strategies to eventually bring it to the marketplace. TLA has filed three patents for technologies behind the device.